Stockscreener 앱 받기
6.38
4.91%
-0.33
전일 마감가:
$6.71
열려 있는:
$6.71
하루 거래량:
59,400
Relative Volume:
0.59
시가총액:
$162.41M
수익:
-
순이익/손실:
$-22.38M
주가수익비율:
-4.5248
EPS:
-1.41
순현금흐름:
$-15.54M
1주 성능:
-2.59%
1개월 성능:
+6.25%
6개월 성능:
-31.02%
1년 성능:
-0.46%
1일 변동 폭
$6.23
$6.71
1주일 범위
$6.23
$7.00
52주 변동 폭
$4.44
$11.80
Nuvectis Pharma Inc Stock (NVCT) Company Profile
명칭
Nuvectis Pharma Inc
전화
360-837-7232
주소
1 BRIDGE PLAZA, SUITE 275, FORT LEE
NVCT을(를) 다른 주식과 비교
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
NVCT
Nuvectis Pharma Inc
|
6.38 | 170.82M | 0 | -22.38M | -15.54M | -1.41 |
|
VRTX
Vertex Pharmaceuticals Inc
|
425.24 | 109.11B | 11.39B | 3.64B | 3.50B | 13.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
641.54 | 68.50B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
433.50 | 60.25B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ARGX
Argen X Se Adr
|
825.85 | 50.39B | 3.06B | 1.28B | 447.35M | 19.67 |
|
INSM
Insmed Inc
|
186.20 | 40.44B | 447.02M | -1.18B | -868.57M | -6.1812 |
Nuvectis Pharma Inc Stock (NVCT) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2025-04-02 | 개시 | Maxim Group | Buy |
| 2025-03-17 | 개시 | Laidlaw | Buy |
| 2022-07-13 | 개시 | Ladenburg Thalmann | Buy |
Nuvectis Pharma Inc 주식(NVCT)의 최신 뉴스
Is Nuvectis Pharma Inc a good long term investmentStock Split Announcements & High Yield Market Growth - earlytimes.in
Why Nuvectis Pharma Inc. stock remains undervaluedEarnings Summary Report & Fast Moving Trade Plans - newser.com
How strong is Nuvectis Pharma Inc. stock revenue growthJuly 2025 Short Interest & Weekly Return Optimization Alerts - newser.com
How Nuvectis Pharma Inc. stock performs in rate cut cyclesJuly 2025 Sector Moves & Community Consensus Trade Alerts - newser.com
Using RSI to spot recovery in Nuvectis Pharma Inc.July 2025 Spike Watch & Capital Protection Trading Alerts - newser.com
Predicting Nuvectis Pharma Inc. trend using moving averagesJuly 2025 Recap & Entry Point Confirmation Signals - newser.com
What makes Nuvectis Pharma Inc. stock attractive to growth funds2025 Market Sentiment & AI Forecast Swing Trade Picks - newser.com
Nuvectis Pharma Shares: Poised for Significant Growth? - AD HOC NEWS
Nuvectis Pharma : Initial Statement of Beneficial Ownership (Form 3) - MarketScreener
What data driven models say about Nuvectis Pharma Inc.’s futureMarket Volume Summary & Smart Investment Allocation Insights - newser.com
Does Nuvectis Pharma Inc. qualify in momentum factor screening2025 Price Momentum & Advanced Technical Signal Analysis - newser.com
Insider Buying: Nuvectis Pharma (NASDAQ:NVCT) Major Shareholder Acquires 46,900 Shares of Stock - MarketBeat
Insider Buying: Nuvectis Pharma (NASDAQ:NVCT) Major Shareholder Purchases 72,836 Shares of Stock - MarketBeat
A US$22m Market Cap Boost Pleasing ToNuvectis Pharma Insiders - simplywall.st
What's Driving Renewed Interest In Nuvectis Pharma's Oncology Strategy? - RTTNews
Major Investment Alert: Insider Buys Big in Nuvectis Pharma! - TipRanks
Insider Stock Purchases: October 29, 2025 - Quiver Quantitative
Nuvectis Pharma Stock (NVCT) Opinions on NXP900 Trial Results - Quiver Quantitative
Nuvectis Pharma (NVCT) Expected to Announce Quarterly Earnings on Tuesday - MarketBeat
Nuvectis Pharma Insider Bought Shares Worth $957,083, According to a Recent SEC Filing - MarketScreener
Nuvectis Pharma’s Phase 1 Study of NXP900: A Potential Game-Changer in Cancer Treatment - The Globe and Mail
Can Nuvectis Pharma Inc. stock hit analyst price targetsMarket Volume Summary & Daily Technical Forecast Reports - fcp.pa.gov.br
H.C. Wainwright reiterates Buy rating on Nuvectis Pharma stock at $10 target - Investing.com Nigeria
H.C. Wainwright reiterates Buy rating on Nuvectis Pharma stock at $10 target By Investing.com - Investing.com South Africa
Can Nuvectis Pharma Inc. stock reach $100 price targetJuly 2025 Institutional & Free Technical Pattern Based Buy Signals - fcp.pa.gov.br
Will Nuvectis Pharma Inc. stock beat EPS estimatesWatch List & Consistent Growth Equity Picks - newser.com
Nuvectis Pharma Inc. stock trendline breakdownJuly 2025 Decliners & Short-Term Trading Opportunity Alerts - newser.com
Nuvectis Pharma Provides Poster Presentation Highlights for NXP900 from the 2025 AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics - The Manila Times
Nuvectis (NASDAQ: NVCT): NXP900 PD ≥150 mg/day; Phase 1b underway; no CYP450 induction - Stock Titan
Nuvectis Pharma Inc (NVCT) 재무 분석
매출
순이익
현금흐름
주당 순 이익
Nuvectis Pharma Inc 주식 (NVCT) 내부자 거래
| 내부자 거래 | 관계 | 날짜 | 거래 | 비용 | #주식 | 가치 ($) | #주식 총계 |
|---|---|---|---|---|---|---|---|
| Mosseri Marlio Charles | 10% Owner |
Oct 23 '25 |
Buy |
6.06 |
46,900 |
284,214 |
3,028,706 |
| Mosseri Marlio Charles | 10% Owner |
Oct 24 '25 |
Buy |
6.15 |
35,034 |
215,459 |
3,063,740 |
| Mosseri Marlio Charles | 10% Owner |
Jun 20 '25 |
Buy |
7.99 |
5,603 |
44,768 |
2,981,806 |
| Mosseri Marlio Charles | 10% Owner |
Jun 18 '25 |
Buy |
8.05 |
28,043 |
225,746 |
2,976,203 |
| Mosseri Marlio Charles | 10% Owner |
Jun 17 '25 |
Buy |
8.11 |
5,399 |
43,786 |
2,948,160 |
| Mosseri Marlio Charles | 10% Owner |
May 12 '25 |
Buy |
8.11 |
21,167 |
171,664 |
2,942,761 |
| Mosseri Marlio Charles | 10% Owner |
May 06 '25 |
Buy |
8.59 |
12,444 |
106,955 |
2,896,565 |
| Mosseri Marlio Charles | 10% Owner |
May 07 '25 |
Buy |
8.59 |
12,317 |
105,770 |
2,908,882 |
| Mosseri Marlio Charles | 10% Owner |
May 08 '25 |
Buy |
8.65 |
2,650 |
22,922 |
2,911,532 |
| Mosseri Marlio Charles | 10% Owner |
Feb 07 '25 |
Buy |
5.00 |
240,000 |
1,200,000 |
2,884,121 |
0.29%
0.16%
자본화:
|
볼륨(24시간):